With a revenue increase of 6.83% in the third quarter 2026, year on year to cumulative value of $30,988 million, Gilead Sciences Inc 's revenue per employee grew on a trailing twelve months basis to $ 1,822,824. The productivity of Gilead Sciences Inc 's employees was 0.0%, above the company average.
Within the Healthcare sector Employees of 39 other companies have achieved higher revenue per employee. While revenue/employee total ranking has improved so far to 503, from total ranking in previous quarter at 632. Gilead Sciences Inc has 17,000 employees.

What is Sales per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Revenue per Employee▼

None ▼

Revenue per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GILD Revenue per Employee	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Revenue Change	6.83 %	10.18 %	4.39 %	4.7 %	2.97 %
Sales per Employee (TTM) $	1,822,824	1,791,588	1,749,176	1,731,941	1,711,000
GILD's Total Ranking	# 503	# 632	# 502	# 497	# 502
Seq. Revenue Change	6.37 %	12.11 %	-12.18 %	2.01 %	9.7 %

GILD Company Profile >> Back to GILD Efficiency Comparisons >> Compare GILD Sales per Employee to its Competitors

Revenue per Employee Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 6
Healthcare Sector	# 40
Overall Market	# 503

Revenue per Employee Statistics
High	Average	Low
$ 1,931,706	$ 1,087,918	$ 105,219
(Mar 31 2016)		(Sep. 30, 2005)

Financial Statements
Gilead Sciences Inc 's Revenue MRQ	$ 8,300 Millions	Visit GILD's Income Statement
Gilead Sciences Inc 's Revenues TTM	$ 30,988 Millions	Visit GILD's aggregate revenue growth
What are GILD's Sales?		Visit GILD's Sales by Segment

News about Gilead Sciences Inc Revenue per employee

Gilead Sciences Unveils Groundbreaking Antiviral Data and Manufacturing Innovations, Solidifying Its Leadership...

In a pivotal leap for antiviral research and development, Gilead Sciences, Inc. (Nasdaq: GILD) is set to showcase groundbreaking findings at IDWeek 2025, scheduled from October 19-22 in Atlanta, GA. With a comprehensive agenda featuring 34 presentations on the latest advances in HIV, viral hepatitis, respiratory viruses, and other viruses of pandemic potential, Gilead reinforces its status as a leader in the field of antiviral science. Among these, six presentations will be delivered orally, underscoring the company’s commitment to sharing vital data with the global health community.The illuminating research set for presentation at IDWeek highlights not only Gilead’s innovative therapeutic solutions but also illuminates its ongoing dedication to safeguarding public health. The focus will encompass Gilead s efforts to advance treatments in critical health areas, including novel partnerships, research methodologies, and emerging data from clinical trials that underscore the efficacy of its antiviral candidates across diverse populations.

Other Ratios
Gilead Sciences Inc 's Income per Employee
Employees in Biotechnology & Pharmaceuticals
Biotechnology & Pharmaceuticals Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
GILD's Revenue per Employee versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for GILD's Competitors
Revenue per Employee for GILD's Suppliers
Revenue per Employee for GILD's Customers

You may also want to know
GILD's Sales Growth Rates	GILD's Pe Price to earnings ratio	GILD's Receivables Turnover Ratio	GILD's Stock Quote
GILD's Net Income Growth Rates	GILD's Ps Price to Sales ratio	GILD's Sales per Employee	GILD's Asset Turnover Ratio
GILD's Net Margin	GILD's Pb Price to Book ratio	GILD's Financial Strength Ratios	GILD's Dividend Payout Ratio

Date modified: 2026-10-31T17:28:36+00:00

Companies with similar Revenue per Employee for 12 months ending Sep 30 2026, within Healthcare Sector	Revenue per Employee	Revenue 12 months ending Sep 30 2026	Number of Employees Sep 30 2026
Kiniksa Pharmaceuticals International Plc	2,584,598.36	$ 945.963 Million	366
Aurinia Pharmaceuticals Inc	2,513,578.12	$ 321.738 Million	128
Sarepta Therapeutics Inc	2,342,920.96	$ 1,956.339 Million	835
Zevra Therapeutics Inc	2,304,065.57	$ 140.548 Million	61
Nurix Therapeutics Inc	2,214,309.15	$ 701.936 Million	317
Exelixis Inc	2,176,862.25	$ 2,496.861 Million	1,147
Incyte Corporation	2,113,485.94	$ 6,010.754 Million	2,844
Alnylam Pharmaceuticals Inc	2,005,296.80	$ 5,013.242 Million	2,500
Neurocrine Biosciences Inc	1,850,850.00	$ 3,701.700 Million	2,000
Tarsus Pharmaceuticals Inc	1,843,791.89	$ 682.203 Million	370
Gilead Sciences Inc	1,822,823.53	$ 30,988.000 Million	17,000
Mirum Pharmaceuticals Inc	1,803,166.67	$ 670.778 Million	372
Eli Lilly And Company	1,729,240.00	$ 86,462.000 Million	50,000
Alector Inc	1,684,165.05	$ 173.469 Million	103
Rigel Pharmaceuticals Inc	1,656,396.55	$ 288.213 Million	174
Jazz Pharmaceuticals Plc	1,632,569.55	$ 4,718.126 Million	2,890
Krystal Biotech Inc	1,593,305.08	$ 470.025 Million	295
Madrigal Pharmaceuticals Inc	1,560,590.16	$ 1,427.940 Million	915
Bristol myers Squibb Company	1,539,476.92	$ 50,033.000 Million	32,500
Acadia Pharmaceuticals Inc	1,506,642.86	$ 1,202.301 Million	798
Indivior Pharmaceuticals Inc	1,376,000.00	$ 1,376.000 Million	1,000
Biogen Inc	1,372,973.33	$ 10,297.300 Million	7,500
Supernus Pharmaceuticals inc	1,326,849.69	$ 865.106 Million	652
Corcept Therapeutics Inc	1,320,064.38	$ 963.647 Million	730
Travere Therapeutics Inc	1,309,927.57	$ 651.034 Million	497
Lantheus Holdings Inc	1,309,212.07	$ 1,561.890 Million	1,193
Ptc Therapeutics inc	1,166,048.44	$ 1,155.554 Million	991
Abbvie Inc	1,158,140.35	$ 66,014.000 Million	57,000
Biomarin Pharmaceutical Inc	1,134,780.19	$ 3,655.127 Million	3,221
Bridgebio Pharma Inc	1,126,984.51	$ 945.540 Million	839

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.